Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus In vitro and In vivo

Microb Pathog. 2020 Dec:149:104317. doi: 10.1016/j.micpath.2020.104317. Epub 2020 Jun 5.

Abstract

Introduction: Staphylococcus aureus is a common human pathogen that causes various diseases including infections on the skin, in the bloodstream and the lower respiratory tracts. The emergence of methicillin-resistant S. aureus (MRSA) made the treatment of the bacterial infection more difficult, calling for development of new therapeutics. Compared with conventional antibiotic therapy, phage therapy offers a promising alternative to combat infections caused by MRSA.

Results: Here we showed that phage VB_SauS_SH-St 15644 isolated from sewage inhibited MRSA isolates in vitro and in the murine skin infection model. Phage VB_SauS_SH-St 15644 belongs to Siphoviridae. The genome of the phage is a linear, 45,111 bp double-stranded DNA with GC content of 33.35%. Among the 37 clinical MRSA isolates tested, 12 (32%) were lysed by the phage in vitro. The phage was relatively stable at temperatures up to 40 °C or between pH 6 and 9. However, the phage was sensitive to UV light. 80% of the phage was approximately adsorbed to the host MRSA isolate in 4 min. The one-step growth curve showed that the latent period was about 12 min followed by the growth period (about 9 min). The burst size was estimated at 13 PFU per infected cell. Furthermore, in a murine skin infection model, the phage significantly inhibited MRSA infection.

Conclusions: Our study suggested that phage VB_SauS_SH-St 15644 has a potential to inhibit MRSA skin infection.

Keywords: Bacteriophage; Characterization; Mouse model; Skin infection; Staphylococcus aureus.

MeSH terms

  • Animals
  • Bacteriophages* / genetics
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Mice
  • Siphoviridae*
  • Staphylococcal Infections* / therapy
  • Staphylococcus aureus